search

News Releases

Search

Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application
~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved,...
April 7, 2026
Coeptis Receives Shareholder Approval Towards Z Squared Merger
Shareholder Approval Clears a Key Condition to Close WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced that its shareholders have voted to approve the...
February 5, 2026
Coeptis Therapeutics Holdings, Inc. Footer Logo

Coeptis Therapeutics Holdings, Inc.

Corporate Headquarters
105 Bradford Road, Suite 420
Wexford, PA 15090
+1 (724) 934-6467

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission. The statements that are not historical facts contained in releases or in our posted events and presentations are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings. Coeptis Therapeutics Holdings, Inc. does not undertake any obligation to update forward-looking statements after the date of such releases except to the extent required under applicable federal and state securities laws. This website contains links to websites maintained by other companies. Coeptis Therapeutics is providing these links to readers only as a convenience. The inclusion of any link does not imply that Coeptis Therapeutics endorses any third-party website or third-party company or product. Coeptis Therapeutics does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.

© Copyright Coeptis Therapeutics Holdings, Inc. 2026